Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up

Jin Sung Park, Hye Gyung Kim, Jin Hong Shin, Youngchul Choi, Dae Seong Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Late-onset Pompe disease (LOPD) is an autosomal recessive disorder caused by deficiency of the enzyme acid glucosidase alfa (GAA). Recently, enzyme replacement therapy (ERT) using recombinant human GAA (rhGAA) became clinically available, and is expected to modify the clinical course in LOPD of various stages. In this study, we evaluated the efficacy and adverse events of ERT for 48 weeks in Korean LOPD patients. Five Korean LOPD patients were included in the study. At baseline, clinical and laboratory features, including muscular and pulmonary function, were assessed, and rhGAA was infused every 2 weeks. Then, patients were examined at every 12-week interval for evaluation of changes in motor and pulmonary function for 48 weeks along with adverse reactions to ERT. The muscular and pulmonary function of the patients varied depending on the baseline condition of the patient after 48 weeks of ERT. However, the overall function of the patients showed stabilization of the disease rather than the improvement seen in infantile-onset Pompe disease. This is the first clinical study on ERT of Korean LOPD patients. Results of our study showed stabilization of muscular and pulmonary function in LOPD patients for 48 weeks with a favorable prognosis for patients who received early diagnosis and ambulatory patients. One of our patients developed a serious anaphylactic reaction, which necessitated the cessation of further ERT. Therefore, our study shows that early diagnosis and ERT are important in preventing further deterioration of the disease.

Original languageEnglish
Pages (from-to)599-605
Number of pages7
JournalNeurological Sciences
Volume36
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Glycogen Storage Disease Type II
Enzyme Replacement Therapy
Lung
Early Diagnosis
Late Onset Disorders
Glucosidases
Anaphylaxis

All Science Journal Classification (ASJC) codes

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Park, Jin Sung ; Kim, Hye Gyung ; Shin, Jin Hong ; Choi, Youngchul ; Kim, Dae Seong. / Effect of enzyme replacement therapy in late onset Pompe disease : open pilot study of 48 weeks follow-up. In: Neurological Sciences. 2015 ; Vol. 36, No. 4. pp. 599-605.
@article{cad59f5d9e684ea583b9700bacb53df5,
title = "Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up",
abstract = "Late-onset Pompe disease (LOPD) is an autosomal recessive disorder caused by deficiency of the enzyme acid glucosidase alfa (GAA). Recently, enzyme replacement therapy (ERT) using recombinant human GAA (rhGAA) became clinically available, and is expected to modify the clinical course in LOPD of various stages. In this study, we evaluated the efficacy and adverse events of ERT for 48 weeks in Korean LOPD patients. Five Korean LOPD patients were included in the study. At baseline, clinical and laboratory features, including muscular and pulmonary function, were assessed, and rhGAA was infused every 2 weeks. Then, patients were examined at every 12-week interval for evaluation of changes in motor and pulmonary function for 48 weeks along with adverse reactions to ERT. The muscular and pulmonary function of the patients varied depending on the baseline condition of the patient after 48 weeks of ERT. However, the overall function of the patients showed stabilization of the disease rather than the improvement seen in infantile-onset Pompe disease. This is the first clinical study on ERT of Korean LOPD patients. Results of our study showed stabilization of muscular and pulmonary function in LOPD patients for 48 weeks with a favorable prognosis for patients who received early diagnosis and ambulatory patients. One of our patients developed a serious anaphylactic reaction, which necessitated the cessation of further ERT. Therefore, our study shows that early diagnosis and ERT are important in preventing further deterioration of the disease.",
author = "Park, {Jin Sung} and Kim, {Hye Gyung} and Shin, {Jin Hong} and Youngchul Choi and Kim, {Dae Seong}",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s10072-014-2000-5",
language = "English",
volume = "36",
pages = "599--605",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia",
number = "4",

}

Effect of enzyme replacement therapy in late onset Pompe disease : open pilot study of 48 weeks follow-up. / Park, Jin Sung; Kim, Hye Gyung; Shin, Jin Hong; Choi, Youngchul; Kim, Dae Seong.

In: Neurological Sciences, Vol. 36, No. 4, 01.04.2015, p. 599-605.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of enzyme replacement therapy in late onset Pompe disease

T2 - open pilot study of 48 weeks follow-up

AU - Park, Jin Sung

AU - Kim, Hye Gyung

AU - Shin, Jin Hong

AU - Choi, Youngchul

AU - Kim, Dae Seong

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Late-onset Pompe disease (LOPD) is an autosomal recessive disorder caused by deficiency of the enzyme acid glucosidase alfa (GAA). Recently, enzyme replacement therapy (ERT) using recombinant human GAA (rhGAA) became clinically available, and is expected to modify the clinical course in LOPD of various stages. In this study, we evaluated the efficacy and adverse events of ERT for 48 weeks in Korean LOPD patients. Five Korean LOPD patients were included in the study. At baseline, clinical and laboratory features, including muscular and pulmonary function, were assessed, and rhGAA was infused every 2 weeks. Then, patients were examined at every 12-week interval for evaluation of changes in motor and pulmonary function for 48 weeks along with adverse reactions to ERT. The muscular and pulmonary function of the patients varied depending on the baseline condition of the patient after 48 weeks of ERT. However, the overall function of the patients showed stabilization of the disease rather than the improvement seen in infantile-onset Pompe disease. This is the first clinical study on ERT of Korean LOPD patients. Results of our study showed stabilization of muscular and pulmonary function in LOPD patients for 48 weeks with a favorable prognosis for patients who received early diagnosis and ambulatory patients. One of our patients developed a serious anaphylactic reaction, which necessitated the cessation of further ERT. Therefore, our study shows that early diagnosis and ERT are important in preventing further deterioration of the disease.

AB - Late-onset Pompe disease (LOPD) is an autosomal recessive disorder caused by deficiency of the enzyme acid glucosidase alfa (GAA). Recently, enzyme replacement therapy (ERT) using recombinant human GAA (rhGAA) became clinically available, and is expected to modify the clinical course in LOPD of various stages. In this study, we evaluated the efficacy and adverse events of ERT for 48 weeks in Korean LOPD patients. Five Korean LOPD patients were included in the study. At baseline, clinical and laboratory features, including muscular and pulmonary function, were assessed, and rhGAA was infused every 2 weeks. Then, patients were examined at every 12-week interval for evaluation of changes in motor and pulmonary function for 48 weeks along with adverse reactions to ERT. The muscular and pulmonary function of the patients varied depending on the baseline condition of the patient after 48 weeks of ERT. However, the overall function of the patients showed stabilization of the disease rather than the improvement seen in infantile-onset Pompe disease. This is the first clinical study on ERT of Korean LOPD patients. Results of our study showed stabilization of muscular and pulmonary function in LOPD patients for 48 weeks with a favorable prognosis for patients who received early diagnosis and ambulatory patients. One of our patients developed a serious anaphylactic reaction, which necessitated the cessation of further ERT. Therefore, our study shows that early diagnosis and ERT are important in preventing further deterioration of the disease.

UR - http://www.scopus.com/inward/record.url?scp=84928229575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928229575&partnerID=8YFLogxK

U2 - 10.1007/s10072-014-2000-5

DO - 10.1007/s10072-014-2000-5

M3 - Article

C2 - 25388776

AN - SCOPUS:84928229575

VL - 36

SP - 599

EP - 605

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 4

ER -